Effect of SGLT2 inhibitor empagliflozin on the stabilization of heart failure progress with the possibility of further interventions in a patient with HFrEF – a case report

Česká verzia

Authors: Filip Málek
Authors place of work: Kardiovaskulární centrum, Nemocnice Na Homolce, Praha
Published in the journal: Vnitř Lék 2022; 68(7): 454-457
Category: Case reports
doi: https://doi.org/10.36290/vnl.2022.095

Summary

SGLT2 inhibitors are included in the first line medical therapy of HFrEF. We report a case study of a patient in whom introduction of treatment with empagliflozin after recurrent heart failure decompensation lead to stabilization of the progress of the disease. Heart failure progress stabilization enabled interventions of cardiovascular comorbidities with delay of heart transplantation or mechanical assist device implantation need.

Keywords:

empagliflozin – heart failure progress – stabilization

Zdroje

1. Packer M, Anker SD, Butler J et al. For the EMPEROR‑Reduced Trial Investigators Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureN Engl J Med 2020 383,15:1413-24

2. Mc Donagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; doi:10.1093/eurheartj/ehab368